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Abstract 
Background: Therapeutic mammaplasty (TM) which combines breast reduction and mastopexy 
techniques with tumour excision, may extend the boundaries of breast-conserving surgery (BCS) and 
improve outcomes for patients, but current practice is unknown and high-quality outcome data is lacking.  
This prospective multicentre cohort study aimed to explore the practice and short-term outcomes of the 
technique.   
 
Methods: Consecutive patients undergoing TM at participating centres between 1st September,2016 and 
30th June,2017 were recruited to the study. Demographic, pre-operative, operative, oncological and 
complication data were collected. The primary outcome was unplanned re-operation for complications 
within 30 days of surgery. Secondary outcomes included re-excision rates and time to adjuvant therapy.   
 
Results: Overall 880 patients underwent 899 TM procedures at 50 centres. The most common 
indications for TM were avoidance of poor cosmetic outcomes associated with standard BCS (n=702, 
78.1%) or avoidance of mastectomy (n=379, 42.2%). Wise-pattern skin incisions were the most common 
(n=429, 47.7%) but a range of incisions and nipple/areola pedicles were used. Immediate contralateral 
symmetrisation was performed in one-third of cases (n=284, 32.2%). In total, 205 (23.3%) patients 
experienced a complication but <3%(n=25) required re-operation. Median lesion size was 24.5mm 
(interquartile range (IQR) 16-38mm). Incomplete excision was seen in 132 cases (14.7%) but only 51 
(5.8%) patients ultimately required mastectomy. Median time to adjuvant therapy was 54 days (IQR 42-
66). 
 
Conclusion: Therapeutic mammaplasty is a safe and effective alternative to mastectomy or standard 
BCS. Further work is now required to explore the impact of the technique on quality of life and establish 
cost-effectiveness. 
 
  
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
3 
 
Introduction 
Breast conserving surgery (BCS) with adjuvant radiotherapy is an established treatment for early breast 
cancer1 2. While many women may prefer breast conservation to mastectomy, standard BCS can often 
result in unacceptable cosmetic outcomes3 4 which may adversely impact on patient satisfaction and 
quality of life5-8. 
Therapeutic mammaplasty (TM) describes ‘the oncoplastic application of breast reduction and mastopexy 
techniques to treat selected breast cancers by BCS’9 10. These techniques effectively extend the 
boundaries of traditional BCS by allowing adequate resection of larger tumours in women with medium to 
large breasts without compromising cosmetic outcome11-14; provide an alternative to mastectomy 
with/without reconstruction in those with ptotic breasts9 15 and may improve outcomes for women with 
large breasts in whom standard BCS followed by radiotherapy may be associated with lymphoedema, 
fibrosis, and chronic pain16.  
Despite the widespread adoption of these techniques into routine practice, there is limited high-quality 
evidence to support benefits of this approach. TM procedures are more complex than standard BCS with 
potential resource implications.  Although complication rates and oncological safety have been reported in 
the literature16-24 the majority of published studies are retrospective single-centre16 22-24, often single 
surgeon case-series with limited follow-up. Many are poorly-designed and reported, with inconsistent end-
points25 which limit cross-study comparison and meaningful data synthesis. Several recent systematic 
reviews26-34 have highlighted the paucity of high-quality clinical, oncological and cosmetic outcome data 
and emphasised the urgent need for well-designed prospective studies to establish the indications and 
outcomes of TM to inform best practice.   
Although randomised controlled trials (RCTs) provide the best evidence for the effectiveness of an 
intervention, RCTs are largely inappropriate in this context. A high-quality prospective multicentre cohort 
study exploring the practice and outcomes of these techniques is therefore essential to support the safe 
practice of TM, generate guidelines, guide decision-making, and inform health policy.  
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The aim of this study was to describe the current practice of TM including indications and techniques 
used; complication and incomplete tumour excision rates and the impact of TM on the time to delivery of 
adjuvant therapy. The secondary aims were to identify risk factors associated with complications and 
incomplete excision and to develop a network of surgeons performing the technique and engage them in 
the need for evaluation. 
Methods  
Study design and participants 
All breast and plastic surgical units performing TM were invited to participate in this multicentre 
prospective cohort study through the UK breast and plastic surgical trainee research collaborative 
network (Mammary Fold Academic and Research Collaborative and the Reconstructive Surgery Trials 
Network) and the professional associations (Association of Breast Surgery (ABS) and British Association 
of Plastic, Reconstructive and Aesthetic Surgeons, BAPRAS)35. 
Consecutive female patients undergoing TM at participating units between 1st September 2016 and 30th 
June 2017 were prospectively recruited to the study. ‘Therapeutic mammaplasty’ was defined as ‘the 
application of breast reduction or mastopexy techniques, including removal of skin to reduce the skin 
envelope, to treat invasive or ductal carcinoma in situ (DCIS) using BCS’.  Patients undergoing standard 
BCS not involving reduction of the skin envelope; level one oncoplastic techniques involving glandular 
remodelling only or BCS with volume replacement techniques such as local perforator, e.g thoracodorsal 
artery perforator (TDAP), or lateral intercostal artery perforator (LiCAP) flaps or latissimus dorsi mini-flaps 
were excluded. Also excluded were patients undergoing surgery for benign disease and those  
undergoing mastectomy with or without immediate breast reconstruction.  
Demographic, pre-operative planning, operative and oncological data were collected prospectively for all 
patients as previously described35. Recommended adjuvant treatments were identified from post-
operative multi-disciplinary team (MDT) meetings and date of commencement of adjuvant treatment from 
appropriate on-line hospital systems or case-note review.  Complications, readmissions and re-operations 
at 30 days were collected prospectively by clinical review or retrospective review of case-notes in patients 
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not attending for follow-up.  All data were collected by members of the surgical team and managed using 
REDCap data capture software (http://www.projectredcap.org/)36 37.      
This study was classified as service evaluation/clinical audit by the NHS Health Research Authority 
Decision Tool  (http://www.hra-decisiontools.org.uk/research/index.html)  Individual patient consent was 
not required but each participating centre was required to obtain local clinical governance approvals prior 
to commencing patient recruitment.   
Primary outcomes 
The primary outcome was unplanned re-operation for local complications within 30 days of the TM 
procedure.  This included re-operation for any complications of the TM and/or contralateral symmetrising 
procedure but did not include additional surgery for oncological reasons including the need for re-excision 
of margins, completion mastectomy or axillary clearance.  This outcome was selected based on Quality 
Criteria (QC) 16 from the Oncoplastic Breast Surgery: Guidelines for best practice38 which state that less 
than 5% of patients should require return to theatre for complications following oncoplastic breast surgery.  
Specific outcomes of interest included; haematoma requiring surgical evacuation; infection requiring 
surgical drainage or debridement; skin necrosis including the T junction breakdown requiring surgical 
debridement; nipple necrosis or complete nipple loss requiring surgical debridement and wound 
dehiscence requiring return to theatre for re-suturing.  Full definitions of complications used in the study 
have been reported previously35.   
Secondary Outcomes 
Secondary outcomes reflected current best practice38 and NICE guidelines39 and included readmission to 
hospital, incomplete tumour excision requiring further surgery and time to delivery of adjuvant therapy35.  
Readmission to hospital was defined as any readmission following discharge for local or systemic 
complications of surgery as defined in the study protocol35 within 30 days of the index procedure.  
Incomplete tumour excision was defined as invasive tumour or DCIS at, or close to, the resection margin 
requiring further surgery (re-excision or margins or completion mastectomy) as defined by local MDT 
criteria.  Re-excision of margins was defined as return to theatre for removal of additional tissue in a 
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second operation due to one or more involved/positive margins. Completion mastectomy was defined as 
the complete removal of remaining breast tissue as elected by MDT decision or patient choice. Time to 
adjuvant therapy was defined as the time in days from the TM (or last oncological surgery, if further 
surgery was required) to the first adjuvant treatment, i.e. the first dose of chemotherapy or first fraction of 
radiotherapy.    
Data quality assurance 
For quality assurance (QA) purposes, the principal investigator at each site was requested to 
independently validate 5-10% of the data entered from their unit. The validation process involved 
checking and confirming that all entered data for the selected patients were correct. If concordance 
between the number of cases submitted on REDCap and those identiﬁed independently was <90%, the 
unit’s data was excluded from the final analysis. This was consistent with QA procedures used in other 
collaborative studies40.   
Statistical analysis 
Descriptive summary statistics were calculated for each variable to describe the practice and outcomes of 
TM. Categorical data were summarised by counts and percentages. Continuous data was summarised by 
median, interquartile range (IQR) and range. 
Univariable logistic regression analysis was used to explore clinico-pathological variables hypothesised to 
be associated to the outcomes of interest. For complications, these included patient and procedure-
related variables, namely age, smoking, body mass index (BMI), diabetes, co-morbidities, American 
Society of Anesthesiologists (ASA) grade, neoadjuvant chemotherapy, grade and experience of operating 
surgeon, type of skin incision, unilateral vs bilateral surgery, axillary surgery performed, specimen weight, 
drain use and duration of surgery. For incomplete excision, variables considered were patient age, 
neoadjuvant chemotherapy, maximum pre-operative size, pre-operative multifocality and localisation, 
specimen imaging (yes vs no), invasive disease (vs DCIS), positive nodal status (N0 vs N1/N2), positive 
HER-2 status, positive ER status, ductal vs lobular invasive disease on post-operative pathology, grade of 
invasive disease on post-operative pathology, screening (vs symptomatic), and specimen weight. 
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Variables with a p-value <0.1 were carried forward to a multivariable model to identify any independent 
risk factors for each outcome.  P-values of <0.05 in the multivariable analysis were considered to be 
strongly associated with the outcome.All univariable and multivariable analyses had standard errors 
clustered by centre.     
Time to adjuvant therapy was calculated for the cohort as a whole and for patients with and without post-
operative complications. Kaplan-Meier analyses, univariable Cox survival models (with standard errors 
clustered by centre), and the log-rank test were then used to determine whether complications impacted 
on time to delivery of adjuvant therapy.   
STATA 15 (STATA, Inc., Texas) was used for all analyses. 
Results 
Between 1st September 2016 and 30th June 2017, 898 patients were entered onto the REDCap database 
from 50 units across the United Kingdom (n=48) and Europe (n=2). Of these, eight patients underwent 
TMs performed outside the study period; five patients received symmetrising reduction surgery only and 
five records did not provide any details of the patients or surgery performed and were excluded. Some 
880 patients and 899 TM procedures were therefore included in the analysis. 
Patient demographics  
Patient demographics are summarised in Table 1. Median patient age was 56 (range 23-86).  Almost 
40% (n=344, 39.1%) of study participants were classified as obese (BMI >30), 10% were current smokers 
and less than 5% (n=38, 4.3%) were diabetic. Approximately 40% (n=363, 41.3%) had at least one co-
morbidity. Half of patients (n=454, 51.6%) presented with symptomatic breast lesions and the remainder 
presented through a breast screening programme. Surgery was the initial cancer treatment for the 
majority of patients with less than 20% receiving neoadjuvant therapy (n=162, 18.4%) (Table 1).   
Pre-operative tumour assessment and treatment planning 
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Table 2 summarises the pre-operative planning and surgical decision-making for TM. Tumours were a 
median of 24mm (range 2-120mm) on pre-operative imaging with the majority located in the upper outer 
quadrant (n= 379, 43.3%) of the breast. Most lesions were invasive cancers (invasive ductal n=605, 
68.5%, invasive lobular n=79, 9.0%) and almost 20% (n=169, 18.8%) were assessed as being multifocal 
at diagnosis (table 2).   
The most common indication for TM was to avoid an anticipated poor cosmetic outcome associated with 
standard BCS (n=702, 78.1%) but over 40% of patients (n=279, 42.2%) were offered the technique as an 
alternative to mastectomy. Quality of life benefits and avoidance of the sequelae of radiotherapy in large 
breasts were less commonly-cited indications (table 2). Two-thirds of patients (n=590, 65.6%) were 
offered standard BCS as an alternative surgical approach. For the remainder, the only alternative option 
was mastectomy alone (n=375, 41.7%), or with immediate implant-based (n=270, 30.0%) or autologous 
(n=231, 25.7%) reconstruction.  A third of patients (n=283, 32.2%) were offered contralateral 
symmetrisation at the time of their TM procedure (table 2). 
Operative techniques  
Of the 880 patients; 572 (65.6%) underwent a unilateral TM procedure with no simultaneous contralateral 
surgery; 284 (32.3%) underwent a unilateral TM and simultaneous contralateral symmetrising reduction 
or mastopexy; 5 (0.6%) underwent a unilateral TM and a contralateral mastectomy with or without 
immediate reconstruction and 19 (2.2%) underwent bilateral TM procedures. The median operative time 
was 110.5 minutes (range 39-420 minutes) and the majority of cases (n=771, 85.6%) were performed by 
a consultant surgeon with significant experience (>25 cases) in performing this technique (table 3). Two-
thirds (n=600, 66.6%) of lesions required pre-operative localisation of which 170 (19.3%) involved the use 
of bracketing wires or equivalent.   
A wide range of different surgical approaches and techniques were used (table 3). Wise-pattern skin 
incisions were the most common (n=429, 48.0%) with peri- or circumareolar approaches (n=232, 25.7%) 
and vertical scar techniques (n=135, 15.0%) used less frequently. Most TMs preserved the nipple, using a 
central mound (n=225, 28.1%); inferior (n=204, 25.5%) or superiomedial (n=201, 25.2%) pedicle.  Wide 
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local excision specimens had a median weight of 83g (range 6-1515g) and adequacy of tumour excision 
was confirmed in 90% of cases, most commonly using intra-operative specimen radiography (n=785, 
87.3%). Total TM excision weights ranged from 5-2522g with a median of 126.5g and drains were used in 
a third (n=296, 32.9%) of cases. Symmetrising reductions were most likely to be performed using a Wise-
pattern skin incision (n=232, 81.7%) and a superiomedial (n=112, 39.7%) or inferior (105, 36.6%) nipple 
pedicle. The median reduction weight was 320g (range 0-2477g) (data not shown).  40% (n=351) patients 
had their TM procedure as a day case procedure and a quarter (n=232) went home the day following 
surgery as a 23 hour stay.   
Reoperation and readmission for surgical complications  
Less than 3% (n=25, 2.8%) patients required re-operation for a complication of their surgery and only 12 
(1.4%) patients were readmitted but in total, 205 (23.3%) patients experienced at least one post-operative 
complication within the first 30 days of surgery. These were generally minor complications which were 
managed on an outpatient basis and included infections requiring oral antibiotics (n=70, 8.0%) and wound 
healing problems managed conservatively with dressings (skin necrosis n=77, 8.8%; wound dehiscence 
n=49, 5.6%) (table 4).  
Univariable analyses identified smoking, obesity, ASA grade, surgical experience, Wise-pattern skin 
incisions, bilateral surgery, specimen weight and the use of drains as risk factors associated with post-
operative complications (table 5). Smoking, obesity, higher ASA grade, a less experienced surgeon, and 
a wise pattern skin incision remained strongly associated with post-operative complications in the 
multivariable model. Procedure duration was associated with complications in the univariable analysis but 
only 45% of records contained this variable so this was not included in the multivariable analysis. 
Re-excision and completion mastectomy rates 
Post-operative oncological data split according to whether resection margins were clear, are summarised 
in table 6. Incomplete excision according to local criteria was reported in 132 (14.7%) cases.   Tumours 
with positive margins were more likely to be multifocal (59/132, 44.7% vs 133/744, 17.8%) and larger 
(median 39mm, IQR 25-54mm vs median 23mm, IQR 15-34mm) than those in whom excision margins 
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were clear (table 6).   Management of incomplete excision in the study cohort is shown in figure 1. Re-
excision of margins was successfully performed in 68 cases giving on overall breast conservation rate of 
90.3% (n=812), Completion mastectomy +/- immediate breast reconstruction was required for 43 
(n=4.8%) patients during the study, with a further 8 patients planned for surgery following completion of 
adjuvant chemotherapy. The completion mastectomy rate was therefore 51/899, 5.7% (figure 1). 
Univariable analyses identified maximum pre-operative tumour size, and pre-operative assessment of 
multifocality as potential risk factors for incomplete excision (table 7). Both variables remained strongly 
associated with incomplete excision in the multivariable model. 
Time to adjuvant therapy 
Adjuvant treatment recommendations are summarised in table 8. Adjuvant chemotherapy was 
recommended for 273 (31.0%) patients of whom 228 (83.5%) accepted treatment and adjuvant 
radiotherapy was recommended for 794 (90.2%) patients. 811 (92.2%) patients accepted either post-
operative chemotherapy and/or radiotherapy and the median time for last oncological surgery to first 
adjuvant treatment was 54 days (IQR 42-66). There was no significant difference in time to start of 
adjuvant therapy in patients with and without post-operative complications, OR 0.88 (0.76, 1.03) 
(p=0.109) (log-rank test p=0.147) (Figure 2). 
Discussion 
Therapeutic mammaplasty may provide women with a safe alternative to mastectomy or offer improved 
cosmetic and quality of life outcomes compared with standard BCS, but high-quality evidence to support 
the safety and effectiveness of the technique is lacking26 27. This is the first large prospective multicentre 
cohort study to assess the current practice and short-term outcomes of the technique and provide ‘real 
world’ data from 50 centres regarding complications, rates and management of incomplete excision and 
impact of TM procedures on delivery of adjuvant therapy.  
Although most women are offered TM to avoid poor cosmetic outcomes associated with standard BCS, 
over 40% of patients are offered TM to avoid mastectomy. As the majority of women receiving TM in this 
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study have high BMIs and comorbidities that may make them unsuitable or high risk for immediate breast 
reconstruction, the procedure may have particular quality of life benefits in this group. TM appears to be a 
specialist procedure as it is performed predominantly by consultant surgeons with significant experience 
of the technique. Although Wise-pattern mammaplasties were the most common, a wide range of 
incisions and nipple pedicles were used. The varied techniques encompassed by ‘Therapeutic 
Mammaplasty’ mirror the dominant methods of breast reduction surgery but are likely to also reflect 
tailoring of approach to the tumour and patient as well as surgeon preference and experience. 
Simultaneous contralateral symmetrising reduction/mastopexy procedures were performed in only a third 
of patients. Reasons for this were not addressed but may include patient or surgeon preference or local 
funding issues but given the potential impact that delayed symmetrisation may have on quality of life with 
little if any improvements in overall symmetry, , these reasons are worthy of further study. 
Two thirds of all TM procedures were performed either as a day-case or with a 23 hour stay, consistent 
with the length of stay required for standard BCS or mastectomy. Major complication rates were low with 
less than 3% of patients requiring re-operation for a complication of their TM and/or symmetrising 
procedure, significantly less than the 5% recommended in the Oncoplastic Surgery Guidelines38. 
Complications were associated with smoking, high BMI, Wise-pattern skin incisions, ASA grade and  
surgical experience but not with contralateral symmetrising surgery.  
Median pathological tumour size was 24.5mm but over 20% (n=195) of patients had excisions of lesions 
>40mm, the traditional maximum size for standard BCS. Over 80% of patients undergoing TM had 
complete tumour excision as defined by local MDT criteria with a further 7.6% achieving this with one or 
more margin re-excisions giving an overall breast conservation rate of over 90%. Only 51 (5.7%) patients 
ultimately required a mastectomy and of these, 20 (39.2%) also had immediate reconstruction. Large pre-
operative tumour size and multifocality were the only factors associated with incomplete excision in the 
multivariable model. This and the rate of re-excision is consistent with other studies of standard breast 
conserving surgery41 42, but in these studies, the median tumour size is almost 10mm smaller and the 
proportion of T2 tumours 25% less than the current study. The implication is that TM can achieve similar 
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rates of complete excision (and completion mastectomy) for large cancers as simple BCS techniques in 
small cancers. 
811 (92.2%) patients required adjuvant chemotherapy and/or radiotherapy and the median time to 
adjuvant therapy was 54 days. This was not affected by complications and the interval is concordant with 
that of other studies on different surgical approaches43. TM does not therefore affect time to start adjuvant 
therapy.  
The ‘real world’ outcome data generated from the multicentre TeaM study are remarkably consistent with 
the complication and re-excision rates reported in other series of oncoplastic surgery in the literature in 
which TM formed at least part of the oncoplastic approach27 29 34. The most recent review of ten large 
studies reports complication rates ranging between 8.9 and 24.6%44. It is not clear whether these rates 
are per breast or per patient, but our complication rates of 20.1% per breast and 23.3% per patient are 
broadly comparable. Incomplete excisions were reported in between 5.8 to 18.9% of cases in these 
studies leading to completion mastectomy rates of between 2.9 and 12.5%44. We report incomplete 
excision in less than 15% of cases and a rate of completion mastectomy of less than 6%.  While this is 
reassuring, such comparisons may not be entirely valid due to the heterogeneity of procedures included 
in these studies44 and the lack of consistency of the outcomes assessed25. Many studies and 
subsequently systematic reviews report outcomes of ‘oncoplastic breast conservation’. This term is often 
used to describe a wide range of volume replacement (e.g. LiCAP flaps) and volume displacement 
techniques and procedures ranging in complexity from a small amount of glandular remodelling to 
oncoplastic breast reductions often with contralateral symmetrising procedures which are not directly 
comparable. A number of classification systems have been proposed, most notably Clough’s bi-level 
classification45, but standard adoption of an agreed terminology is a major barrier to high-quality 
comparable research27 46 47. Recently attempts at standardisation have been proposed but terminology 
and algorithms for decision-making are complex and the success of this approach is yet to be 
determined48. The agreement regarding the need for standardised outcome assessment including 
standard definitions of complications and quality of life assessments using validated patient-reported 
outcome measures however must be a priority if future research in oncoplastic surgery is to be 
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meaningful47 and the recently developed core outcome set for reconstructive breast surgery is one may 
by which this may be achieved49.   
This study has provided much needed prospective multicentre evidence for the short-term clinical safety 
and effectiveness of TM but it has several limitations that require consideration. The main limitation is that 
this is a short-term clinical study that has not considered the patient-reported, cosmetic and long-term 
oncological outcomes of the technique.  Whilst this is a significant limitation, one of the main aims of the 
study was to define current practice to inform the design and conduct of a future definitive research study 
and to develop a network of centres performing TM to participate in the project. Given the uncertainty 
regarding patient selection; the techniques used and management of the contralateral breast, this 
preliminary work was an essential prerequisite to developing a future study which will more accurately 
reflect current practice.  Furthermore, the existing cohort will be used to explore long-term oncological 
outcomes in a future data-linkage study to provide added value. This study has collected data from 48 
centres in the UK and 2 centres in Europe and is the largest prospective cohort of this kind. It is possible 
that participating units are high-volume highly specialist centres and that the outcomes reported are not 
representative of those seen at lower volume centres. However, the 48 centres included represent 
approximately one third of all breast units in the UK50 and the similarity of the outcomes with the 
published literature suggests that this is not the case. The observational study design introduces the 
possibility of a number of forms of bias but several steps were taken to minimise this including publishing 
the study protocol a priori; providing clear inclusion and exclusion criteria and ensuring participating units 
recruited consecutive patients; developing standardised outcome definitions and where possible using 
‘hard’ outcomes such as re-operation; margin positivity and treatment start dates which are unambiguous 
and not open to interpretation. Despite this, we acknowledge that our cohort is heterogenous including a 
range of procedures and techniques, but this is itself an important finding in terms of informing future 
studies. Finally, this was a trainee collaborative study, so it is possible that the quality of the data could be 
questioned. Robust quality assurance processes, however were used and none of the centres were 
excluded because of concerns regarding data completeness or accuracy. Despite these limitations, 
therefore, the TeaM study adds significantly to the evidence base in oncoplastic breast surgery, provides 
much needed data to inform decision-making and will inform future research. 
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Therapeutic mammaplasty may offer significant benefits to both patients and service providers but further 
work is needed to robustly define and quantify these benefits to support the ongoing provision of 
specialist care. TM was offered to over 40% of patients in our study as an alternative to mastectomy and 
allowing patients to avoid mastectomy may be one specific area where TM may be used to optimal 
benefit.  Recent work comparing the outcomes of patients undergoing TM and those undergoing 
mastectomy and immediate breast reconstruction suggests that TM may be associated with fewer 
complications51 and better body image, function and quality of life than mastectomy and reconstruction52. 
Further work is needed but TM may also be a more cost-effective approach as many of the patients in 
this cohort would still require post-mastectomy radiotherapy which may adversely impact the outcomes of 
immediate reconstruction, especially if implant-based techniques were used53. More importantly, many of 
the patients who would be offered TM including those with co-morbidities and a high BMI would often not 
be offered immediate reconstruction so the benefits of TM vs. mastectomy alone in these women may be 
significant.  Other groups who may experience particular benefit are those patients with large breasts in 
whom radiotherapy may result in significant complications16. There is ongoing research into how to 
identify patients at high risk of radiotherapy side-effects using biomarkers and clinical predictors54.  While 
this was an indication in less than 20% of our cohort, it may have an increasing role for BCS with 
increasing BMI (and breast size).  Patients may request this form of surgery as awareness of these 
techniques grows and further work is needed to support this approach and to inform the optimal timing of 
contralateral symmetrisation when TM procedures are offered. Randomised clinical trials comparing TM 
with other techniques are largely inappropriate due to patient and surgeon preference and mounting 
evidence to suggest long-term survival benefits for patients undergoing BCS and radiotherapy compared 
to mastectomy55-57. Well-designed prospective cohort studies incorporating validated patient-reported 
outcome measures such as the BREAST-Q58, robust assessments of cosmetic outcome and appropriate 
health economic assessments may provide the best evidence of effectiveness. This preliminary work will 
ensure that any future study reflects current practice and addresses issues that are important to patients 
and the reconstructive community.     
Therapeutic mammaplasty is safe and effective and may provide a better alternative to mastectomy or 
standard BCS for many women. Further work is now needed to establish key patient-reported and longer-
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term oncological outcomes and demonstrate cost-effectiveness so that this promising technique can 
become the new standard of care.   
 
Authors’ contributions 
Conception and design of study EB, TR, AT, SP, RDM; data acquisition RLO’C, TR, EB, SP; data 
analysis and interpretation AT, RLO’C, LW, SP, RDM.  RLO’C wrote the first draft of the manuscript.  All 
authors critically revised the intellectual content and approved the manuscript prior to submission.         
Conflicts of interest 
The authors have no conflicts of interest to declare. 
Funding 
This work is funded by an Association of Breast Surgery Research Grant. SP is funded by an NIHR 
Clinician Scientist award. 
Collaborators  
The TeaM Steering Group (in alphabetical order) were: Rajgopal Achuthan, Shweta Aggarwal, 
Elizabeth Baker, Naren Basu, Lisa Brock, Patricia Fairbrother, Matthew D Gardiner, Chris Holcombe, 
Charlotte Ives, Abhilash Jain, Baek Kim, R Douglas Macmillan, John Murphy, Shelley Potter, Tim Rattay, 
Dennis Remoundos, Richard Sutton, Adam Trickey, Philip Turton, Kathryn Williams.  
Local investigators (alphabetically by centre) and members of the Mammary Fold Academic and 
Research Collaborative were: Aberdeen Royal Infirmary, NHS Grampian: Caitlin MacLeod, Elizabeth 
Smyth, Ivan Depasquale, Mairi Fuller, Nina Saeed, Yazan Masannat. Addenbrookes Hospital, 
Cambridge Universities NHS Foundation Trust: Amir Tan Mohd-Amin, Amit Agrawal. Belfast City 
Hospital, Belfast Health and Social Care Trust: Gareth Irwin, Sam Sloan, Sigi Refsum, Stuart 
McIntosh. Breast Care Centre, North Bristol NHS Trust, Southmead Hospital, Bristol: Abdulla 
Ibrahim, Ajay Sahu, Sasirekha Govindarajulu, Simon Cawthorn. Breast Unit Department. University of 
Naples “Federico II”, Naples, Italy: Antonello Accurso. Brighton and Sussex University Hospitals 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
16 
 
NHS Trust:  Rathi Rathinaezhil. Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust: 
Alex Wilkins, Eiman Khalifa, Kartikae Grover, Penny McManus, Peter Kneeshaw, Tapan Mahapatra. 
Chesterfield Royal Hospital NHS Foundation Trust: Iman Azmy, Julia Massey. Darent Valley 
Hospital, Dartford and Gravesham NHS Trust: Pawel Trapszo, Risha Lane, Seema Seetharam. 
Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy: Nicola 
Rocco. East Cheshire NHS Trust: Chandeena Roshanlall, Jalal Kokan, Khalid Amin. Edinburgh Breast 
Unit, Western General Hospital, NHS Lothian: Alexander Leeper, Dhananjay Kulkarni, JM Dixon, 
Oliver Young, Talha Saleem. Forth Valley Royal Hospital, NHS Forth Valley: Jennifer McIlhenny. 
Gartnavel General Hospital, NHS Greater Glasgow and Clyde: Andy Malyon, James Mansell, Keith 
Ogsto, Laszlo Romics. Glenfield Hospital, University Hospitals of Leicester: Dimitris Dragoumis, 
Jaroslaw Krupa, Kalliope Valassiadou, Kelly Lambert, Monika Kaushik, Shelia Shokuhi, Simon Pilgrim, 
Xiang Wei Jonathan Lee. Gloucestershire Hospital NHS Foundation Trust: Asmaa Al-Allak, Clare 
Fowler, Eleanore Massey, Fiona Court, Richard Hunt, Sarah Vestey. Good Hope Hospital, Heart of 
England NHS Foundation Trust: Haitham Khalil. Heatherwood and Wexham Park Hospital, Frimley 
Health NHS Foundation Trust: Mohsen Elgammal. Homerton University Hospital NHS Foundation 
Trust:  Laila Parvanta. Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust: A S Sami, 
Anzors Gvaramadze, Dinesh Thekkinkattil. Luton and Dunstable University Hospital: Katharine 
Kirkpatrick, Ruth James. Mid Yorkshire Hospitals NHS Trust: Arish Noshirwani, Tehera Arif, Zbigniew 
Kryjak. Milton Keynes University Hospital NHS Foundation Trust: Amanda Taylor, Farah H Syed, 
Gazalla Safdar, Kian Chin, Rachel Soulsby. Musgrove Park Hospital, Taunton and Somerset NHS 
Foundation Trust: Amanda Thorne, Francesca Guest, Mohammed El-Abbar. Ninewells Hopsital, NHS 
Tayside:  D.Alex Munnoch, E.Jane Macaskill, Fiona Hogg, Pauline McGee, Vassilis Pitsinis. Northern 
Lincolnshire and Goole NHS Foundation Trust: Jenny Smith, Sundus Makkiyah, Syed Mustafa. 
Nottingham Breast Institute, Nottingham University Hospitals NHS Trust: Charlene Otieno, Dana 
Photiou, Douglas Macmillan, Ellie Gutteridge, Fayyaz Mazari, Georgette Oni, Hazem Khout, Jennett 
Kelsall, Kelly Hallam, Kristjan Asgeirron, Lisa Whisker, Marta D'Auria, Samim Al-zubaidi, Stephen 
McCulley, Tuabin Rasheed, James Bailey, Lisa Brock, Nazli Muhibullah. Oxford University Hospitals 
NHS Foundation Trust: Alexandra Tenovici, Dionysios-Dennis Remoundos, Nikos Chaidos, Oana 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
17 
 
Predescu, Pankaj Roy, Rebecca Windle. Peterborough City Hospital, North West Anglia NHS 
Foundation Trust: Elena Popa, Geeta Shetty, Jan Rezulski, Steven Goh, Tholkifl Abdullah. Pilgrim 
Hospital Boston, United Lincolnshire Hospitals NHS Trust: Dinesh Thekkinkattil. Prince Philip 
Hospital, Hywel Dda University Health Board: Saira Khawaja, Sujatha Udayasankar. Princess 
Alexandra Hospital NHS Trust: Sally Tebbal, Veronica Grassi. Queen Elizabeth Hospital 
Birmingham, University Hospitals Birmingham NHS Foundation Trust: Adam Talbot, Naren Basu, 
Jagdeep Singh. Royal Bolton Hospital, Bolton NHS Foundation Trust: Amy Smith, Angela 
Volleamere, Clare Garnsey, Panagiotis Pikoulas. Royal Devon and Exeter NHS Foundation Trust: 
Charlotte Ives, Douglas Ferguson, Rachel Tillett, Sarah Dean, Sisse Olsen. Royal Hampshire County 
Hospital, Hampshire Hospitals NHS Foundation Trust: Dick Rainsbury, Lashan Peiris, Olivia Sjokvist, 
Siobhan Laws. Royal Liverpool and Broadgreen University Hospitals NHS Trust: Anne Tansley, 
Emma De Sousa, Geraldine Mitchell, Julia Henderson, Mysore Chandrashekar, Shelley Potter. Royal 
Marsden NHS Foundation Trust: Aikaterini Micha, Amy Godden, Bernadette Pereira, Chloe 
Constantinou, Jennifer Rusby, Katherine Krupa, Natalie To, Peter Barry. Royal Victoria Infirmary, 
Newcastle Upon Tyne Hospitals NHS Foundation Trust:  Adam Critchley, Baek Kim, Henry Cain, Joe 
O'Donoghue, John Henton, Loraine Kalra, Louise MacLennan, Ruth Bennett, Stewart Nicholson. 
Sant'Andrea Hospital of Rome: Guido Paolini, Luca Francesco Renzi, Santanelli Di Pompeo, Vitto Ria. 
St Bartholomew's Hospital, Barts Health NHS Trust: Jennifer Hu, Laura Johnson, Rebecca S Lewis, 
Sirwan Hadad, Souganthy Sundaramoorthy. St George's University Hospitals NHS Foundation Trust: 
Anup Sharma, Delia Toomey, Dibyesh Banerjee, Sarah Shuk Kay Tang. St. James University Hospital, 
The Leeds Teaching Hospitals NHS Trust: Lauren Taylor, Philip Turton, Raj Achuthan, Shireen 
McKenzie, Tanvir Ahmad. The Pennine Acute Hospitals NHS Trust:  Kate Williams, Mohammed Absar, 
Nabila Nasir. The Ulster Hospital, South Eastern Health and Social Care Trust:  Igor Jerzy Rychlik, 
Lynn Darragh, Ruth Johnston, Stephen Kirk. Torbay and South Devon NHS Foundation Trust: 
Jacqueline Rees-Lee, Michael Green. West Hertfordshire Hospitals NHS Trust: Abhishek Sharma, 
Kelvin Chong, Lee Min Lai. Whipps Cross University Hospital, Barts Health NHS Trust: Jia Choong, 
Shweta Aggarwal, Zaker Ullah. Whiston Hospital, St Helens and Knowsley Teaching Hospitals NHS 
Trust: Leena Chagla, Ommen Koshy, Sonia Bathla, Tamara Kiernan, Ajay Ashok Bhojwani. Wirral 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
18 
 
University Teaching Hospital NHS Foundation Trust: Jonathan Lund, Karen James, Maria Callaghan, 
Raman Vinayagam, Shabbir Poonawala. Worcestershire Acute Hospitals NHS Trust: Jevan Taylor, 
Michelle Mullan, Rachel Bright-Thomas. Wythenshawe Hospital, Manchester University NHS 
Foundation Trust: Ashu Gandhi, Ged Byrne, Ibrahim Ibrahim, James Harvey, John Murphy, Lyndsey 
Highton, Ada Chrysafi, Richard Hawley-Jones Nicola Barnes, Owen Morris, Sumohan Chatterjee, Vinod 
Mathen, Yousef Majeed, Cliona Kirwan. York Teaching Hospital NHS Foundation Trust: Ben Mancey-
Jones, Denna El Sharief, Kailas Munot, Rana Nasr, Richard Frame 
Acknowledgements 
Protocol paper published in International Journal of Surgery Protocols. ‘The TeaM (Therapeutic 
Mammaplasty) study: Protocol for a prospective multi-centre cohort study to evaluate the practice and 
outcomes of therapeutic mammaplasty’ https://doi.org/10.1016/j.isjp.2016.08.001 
The TeaM Steering group would like to acknowledge the contribution of the following individuals: 
Aberdeen Royal Infirmary, NHS Grampian: Edward Cowling, Gabija Lazaraviciute, Rachel Innes, Sara 
Jamshidifard, Tim Gardner. Chesterfield Royal Hospital NHS Foundation Trust:  Isabelle Carty, 
Shazia Khan. Good Hope Hospital, Heart of England NHS Foundation Trust: Pavlos Lampropoulos. 
Homerton University Hospital NHS Foundation Trust: Sarantos Kaptanis. Royal Devon and Exeter 
NHS Foundation Trust: Mina Youssef, Mohammad Masood. Royal Victoria Infirmary, Newcastle 
Upon Tyne Hospitals NHS Foundation Trust: Louise MacLennan.  Sant'Andrea Hospital of Rome: 
Vittoria Amorosi.  
 
References 
1. Fisher B, Anderson S, Bryant J, et al. Twenty-Year Follow-up of a Randomized Trial Comparing Total 
Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast 
Cancer. New England Journal of Medicine 2002;347(16):1233-41. doi: 10.1056/NEJMoa022152 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
19 
 
2. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-Year Follow-up of a Randomized Study Comparing 
Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer. N Engl J Med 
2002;347(16):1227-32. 
3. Clough KB, Cuminet J, Fitoussi A, et al. Cosmetic sequelae after conservative treatment for breast 
cancer: classification and results of surgical correction. Ann Plast Surg 1998;41(5):471-81. 
[published Online First: 1998/11/25] 
4. D'Aniello C, Grimaldi L, Barbato A, et al. Cosmetic results in 242 patients treated by conservative 
surgery for breast cancer. Scand J Plast Reconstr Surg Hand Surg 1999;33(4):419-22. [published 
Online First: 1999/12/30] 
5. Cochrane RA, Valasiadou P, Wilson ARM, et al. Cosmesis and satisfaction after breast-conserving 
surgery correlates with the percentage of breast volume excised. British Journal of Surgery 
2003;90(12):1505-09. doi: 10.1002/bjs.4344 
6. Heil J, Holl S, Golatta M, et al. Aesthetic and functional results after breast conserving surgery as 
correlates of quality of life measured by a German version of the Breast Cancer Treatment 
Outcome Scale (BCTOS). Breast 2010;19(6):470-4. doi: 10.1016/j.breast.2010.05.004 
7. Waljee JF, Hu ES, Ubel PA, et al. Effect of esthetic outcome after breast-conserving surgery on 
psychosocial functioning and quality of life. J Clin Oncol 2008;26(20):3331-7. doi: 
10.1200/JCO.2007.13.1375 
8. Al-Ghazal SK, Fallowfield L, Blamey RW. Does cosmetic outcome from treatment of primary breast 
cancer influence psychosocial morbidity? Eur J Surg Oncol 1999;25(6):571-3. doi: 
10.1053/ejso.1999.0708 
9. McCulley SJ, Macmillan RD. Planning and use of therapeutic mammoplasty—Nottingham approach. 
British Journal of Plastic Surgery 2005;58(7):889-901. doi: 
http://dx.doi.org/10.1016/j.bjps.2005.03.008 
10. Macmillan D, James R, Gale K, et al. Therapeutic mammoplasty. Journal of Surgical Oncology 
2014;110:90-95. 
11. Mansfield L, Agrawal A, Cutress RI. Oncoplastic breast conserving surgery. Gland Surgery 
2013;2(3):158-62. 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
20 
 
12. Piper M, Peled AW, Sbitany H. Oncoplastic breast surgery: current strategies. Gland Surgery 
2015;4(2):154-63. 
13. Bamford R, Sutton R, McIntosh J. Therapeutic mammoplasty allows for clear surgical margins in large 
and multifocal tumours without delaying adjuvant therapy. The Breast 2015;24(2):171-74. doi: 
http://dx.doi.org/10.1016/j.breast.2015.01.003 
14. Schaverien MV, Raine C, Majdak-Paredes E, et al. Therapeutic mammaplasty – Extending indications 
and achieving low incomplete excision rates. European Journal of Surgical Oncology (EJSO) 
2013;39(4):329-33. doi: http://dx.doi.org/10.1016/j.ejso.2013.01.006 
15. Crown A, Wechter DG, Grumley JW. Oncoplastic Breast-Conserving Surgery Reduces Mastectomy 
and Postoperative Re-excision Rates. Annals of Surgical Oncology 2015;22(10):3363-8. 
16. Di Micco R, O'Connell RL, Barry PA, et al. Standard wide local excision or bilateral reduction 
mammoplasty in large-breasted women with small tumours: Surgical and patient-reported 
outcomes. European Journal of Surgical Oncology (EJSO) 2017;43(4):636-41. doi: 
https://doi.org/10.1016/j.ejso.2016.10.027 
17. Harvey J, Henderson J, Patel L, et al. Therapeutic mammaplasty – Impact on the delivery of 
chemotherapy. International Journal of Surgery 2014;12(1):51-55. doi: 
http://dx.doi.org/10.1016/j.ijsu.2013.10.013 
18. Clough KB, van la Parra RFD, Thygesen HH, et al. Long-term Results After Oncoplastic Surgery for 
Breast Cancer: A 10-year Follow-up. Annals of Surgery 2017;Publish Ahead of Print doi: 
10.1097/sla.0000000000002255 
19. De Lorenzi F, Hubner G, Rotmensz N, et al. Oncological results of oncoplastic breast-conserving 
surgery: Long term follow-up of a large series at a single institution: A matched-cohort analysis. 
European Journal of Surgical Oncology 2016;42(1):71-7. 
20. Kahn J, Barrett S, Forte C, et al. Oncoplastic breast conservation does not lead to a delay in the 
commencement of adjuvant chemotherapy in breast cancer patients. European Journal of 
Surgical Oncology (EJSO) 2013;39(8):887-91. doi: http://dx.doi.org/10.1016/j.ejso.2013.05.005 
21. Mansell J, Weiler-Mithoff E, Stallard S, et al. Oncoplastic breast conservation surgery is oncologically 
safe when compared to wide local excision and mastectomy. Breast 2017;32:179-85. 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
21 
 
22. Acea-Nebril B, Cereijo-Garea C, García-Novoa A, et al. The role of oncoplastic breast reduction in the 
conservative management of breast cancer: Complications, survival, and quality of life. Journal of 
Surgical Oncology 2017;115(6):679-86. doi: 10.1002/jso.24550 
23. Carter SA, Lyons GR, Kuerer HM, et al. Operative and Oncologic Outcomes in 9861 Patients with 
Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic 
Reconstruction. Annals of Surgical Oncology 2016;23(10):3190-98. 
24. Wijgman DJ, ten Wolde B, van Groesen NRA, et al. Short term safety of oncoplastic breast 
conserving surgery for larger tumors. European Journal of Surgical Oncology (EJSO) 
2017;43(4):665-71. doi: https://doi.org/10.1016/j.ejso.2016.11.021 
25. Schaverien MV, Doughty JC, Stallard S. Quality of information reporting in studies of standard and 
oncoplastic breast-conserving surgery. The Breast 2014;23(2):104-11. doi: 
http://dx.doi.org/10.1016/j.breast.2013.12.006 
26. McIntosh J, O'Donoghue JM. Therapeutic mammaplasty--a systematic review of the evidence. Eur J 
Surg Oncol 2012;38(3):196-202. doi: 10.1016/j.ejso.2011.12.004 
27. Haloua MH, Krekel NMA, Winters HAH, et al. A Systematic Review of Oncoplastic Breast-Conserving 
Surgery: Current Weaknesses and Future Prospects. Annals of Surgery 2013;257(4):609-20. doi: 
10.1097/SLA.0b013e3182888782 
28. Iwuchukwu OC, Harvey JR, Dordea M, et al. The role of oncoplastic therapeutic mammoplasty in 
breast cancer surgery--a review. Surg Oncol 2012;21(2):133-41. doi: 
10.1016/j.suronc.2011.01.002 [published Online First: 2011/03/18] 
29. Yiannakopoulou EC, Mathelin C. Oncoplastic breast conserving surgery and oncological outcome: 
Systematic review. European Journal of Surgical Oncology (EJSO) 2016;42(5):625-30. doi: 
http://dx.doi.org/10.1016/j.ejso.2016.02.002 
30. Piper ML, Esserman LJ, Sbitany H, et al. Outcomes Following Oncoplastic Reduction Mammoplasty: 
A Systematic Review. Ann Plast Surg 2016;76 Suppl 3:S222-6. doi: 
10.1097/sap.0000000000000720 [published Online First: 2016/01/26] 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
22 
 
31. De La Cruz L, Blankenship SA, Chatterjee A, et al. Outcomes After Oncoplastic Breast-Conserving 
Surgery in Breast Cancer Patients: A Systematic Literature Review. Annals of Surgical Oncology 
2016;23(10):3247-58. doi: 10.1245/s10434-016-5313-1 
32. Yoon JJ, Green WR, Kim S, et al. Oncoplastic breast surgery in the setting of breast-conserving 
therapy: A systematic review. Advances in Radiation Oncology 2016;1(4):205-15. doi: 
https://doi.org/10.1016/j.adro.2016.09.002 
33. Campbell E, Romics L. Oncological safety and cosmetic outcomes in oncoplastic breast conservation 
surgery, a review of the best level of evidence literature. Breast Cancer: Targets and Therapy 
2017;2017(9):521-30. doi: doi.org/10.2147/BCTT.S113742 
34. Losken A, Dugal CS, Styblo TM, et al. A meta-analysis comparing breast conservation therapy alone 
to the oncoplastic technique. Annals of Plastic Surgery 2014;72(2):145-9. 
35. Baker E, Kim B, Rattay T, et al. The TeaM (Therapeutic Mammaplasty) study: Protocol for a 
prospective multi-centre cohort study to evaluate the practice and outcomes of therapeutic 
mammaplasty. International Journal of Surgery Protocols 2016;1:3-10. doi: 
http://dx.doi.org/10.1016/j.isjp.2016.08.001 
36. Obeid JS, McGraw CA, Minor BL, et al. Procurement of shared data instruments for Research 
Electronic Data Capture (REDCap). Journal of Biomedical Informatics 2013;46(2):259-65. doi: 
http://dx.doi.org/10.1016/j.jbi.2012.10.006 
37. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven 
methodology and workflow process for providing translational research informatics support. 
Journal of Biomedical Informatics 2009;42(2):377-81. doi: 
http://dx.doi.org/10.1016/j.jbi.2008.08.010 
38. Rainsbury D, Willett A. Oncoplastic Breast Reconstruction: Guidelines for Best Practice. In: Rainsbury 
R, Willett A, eds.: ABS and BAPRAS, 2012. 
39. National Institute of Clinical Excellence. Breast cancer (early & locally advanced): diagnosis and 
treatment2009. 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
23 
 
40. Vohra RS, Spreadborough P, Johnstone M, et al. Protocol for a multicentre, prospective, population-
based cohort study of variation in practice of cholecystectomy and surgical outcomes (The 
CholeS study). BMJ Open 2015;5(1) doi: 10.1136/bmjopen-2014-006399 
41. Jeevan R, Cromwell DA, Trivella M, et al. Reoperation rates after breast conserving surgery for breast 
cancer among women in England: retrospective study of hospital episode statistics. BMJ : British 
Medical Journal 2012;345:e4505. doi: 10.1136/bmj.e4505 
42. Wilke LG, Czechura T, Wang C, et al. Repeat surgery after breast conservation for the treatment of 
stage 0 to ii breast carcinoma: A report from the national cancer data base, 2004-2010. JAMA 
Surgery 2014;149(12):1296-305. doi: 10.1001/jamasurg.2014.926 
43. The Breast Reconstruction Research C. 1086. Does immediate breast reconstruction delay delivery of 
adjuvant treatment? First results of the iBRA-2 prospective multicentre cohort study. European 
Journal of Surgical Oncology 2017;43(11):2204. doi: https://doi.org/10.1016/j.ejso.2017.10.077 
44. Losken A, Hart A, Chatterjee A. Updated Evidence on the Oncoplastic Approach to Breast 
Conservation Therapy. Plast Reconstr Surg 2017;140(5S):14S-22S. doi: 
10.1097/PRS.0000000000003951 
45. Clough KB, Kaufman GJ, Nos C, et al. Improving Breast Cancer Surgery: A Classification and 
Quadrant per Quadrant Atlas for Oncoplastic Surgery. Annals of Surgical Oncology 
2010;17(5):1375-91. doi: 10.1245/s10434-009-0792-y 
46. Weber WP, Soysal SD, Zeindler J, et al. Current standards in oncoplastic breast conserving surgery. 
Breast 2017;34 Suppl 1:S78-s81. doi: 10.1016/j.breast.2017.06.033 [published Online First: 
2017/07/12] 
47. Weber WP, Soysal SD, El-Tamer M, et al. First international consensus conference on 
standardization of oncoplastic breast conserving surgery. Breast Cancer Res Treat 
2017;165(1):139-49. doi: 10.1007/s10549-017-4314-5 [published Online First: 2017/06/05] 
48. Weber WP, Soysal SD, Fulco I, et al. Standardization of oncoplastic breast conserving surgery. 
European journal of surgical oncology : the journal of the European Society of Surgical Oncology 
and the British Association of Surgical Oncology 2017;43(7):1236-43. doi: 
10.1016/j.ejso.2017.01.006 [published Online First: 2017/02/19] 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
24 
 
49. Potter S, Holcombe C, Ward JA, et al. Development of a core outcome set for research and audit 
studies in reconstructive breast surgery. British Journal of Surgery 2015;102(11):1360-71. doi: 
10.1002/bjs.9883 
50. Duxbury PJ, Gandhi A, Kirwan CC, et al. Current attitudes to breast reconstruction surgery for women 
at risk of post-mastectomy radiotherapy: A survey of UK breast surgeons. The Breast 
2015;24(4):502-12. doi: http://dx.doi.org/10.1016/j.breast.2015.05.002 
51. Tong WM, Baumann DP, Villa MT, et al. Obese Women Experience Fewer Complications after 
Oncoplastic Breast Repair following Partial Mastectomy Than after Immediate Total Breast 
Reconstruction. Plastic & Reconstructive Surgery 2016;137(3):777-91. 
52. Kelsall JE, McCulley SJ, Brock L, et al. Comparing oncoplastic breast conserving surgery with 
mastectomy and immediate breast reconstruction: Case-matched patient reported outcomes. 
Journal of Plastic, Reconstructive and Aesthetic Surgery 2017 
53. Magill LJ, Robertson FP, Jell G, et al. Determining the outcomes of post-mastectomy radiation 
therapy delivered to the definitive implant in patients undergoing one- and two-stage implant-
based breast reconstruction: A systematic review and meta-analysis. Journal of Plastic, 
Reconstructive & Aesthetic Surgery 2017 doi: http://dx.doi.org/10.1016/j.bjps.2017.05.057 
54. West C, Azria D, Chang-Claude J, et al. The REQUITE Project: Validating Predictive Models and 
Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in 
Cancer Survivors. Clinical Oncology 2014;26(12):739-42. doi: 
https://doi.org/10.1016/j.clon.2014.09.008 
55. Hartmann-Johnsen OJ, Kåresen R, Schlichting E, et al. Better survival after breast-conserving therapy 
compared to mastectomy when axillary node status is positive in early-stage breast cancer: a 
registry-based follow-up study of 6387 Norwegian women participating in screening, primarily 
operated between 1998 and 2009. World Journal of Surgical Oncology 2017;15(1):118. doi: 
10.1186/s12957-017-1184-6 
56. Lagendijk M, van Maaren MC, Saadatmand S, et al. Breast conserving therapy and mastectomy 
revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 
patients. International Journal of Cancer 2018;142(1):165-75. doi: 10.1002/ijc.31034 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
25 
 
57. Christiansen P, Carstensen SL, Ejlertsen B, et al. Breast conserving surgery versus mastectomy: 
overall and relative survival—a population based study by the Danish Breast Cancer Cooperative 
Group (DBCG). Acta Oncologica 2018;57(1):19-25. doi: 10.1080/0284186X.2017.1403042 
58. Pusic AL, Klassen A, Scott AF, et al. Development of a new patient-reported outcome measure for 
breast surgery: the BREAST-Q. Plastic and Reconstructive Surgery 2009;124(2):345-53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Short-term outcomes of therapeutic mammaplasty in the TeaM Study 
26 
 
Table 1. Demographics of patients included in the TeaM study 
Patient demographics N=880 patients (%) 
Age, years (median, IQR, range) 56 (50-65) (23-86) 
0-44 years 92 (10.5) 
45-54 years 286 (32.5) 
55-64 years 274 (31.1) 
65-74 years 180 (20.5) 
≥75 years 41 (4.7) 
Not reported 7 (0.8) 
BMI, kg/m2 (median, IQR, range) 
Normal (<25) 
Overweight (≥25 & <30)  
Obese (≥30 & <35) 
Severely obese (>35) 
Not reported 
28.3 (25-32.7) (17.0-58.1) 
200 (22.7) 
309 (35.1) 
213 (24.2) 
131 (14.9) 
27 (3.1) 
Smoking status 
Non-smoker (never smoked) 
Ex-smoker 
Current smoker 
Not reported 
 
642 (73) 
132 (15) 
89 (10.1) 
17 (1.9) 
Co-morbidities 
Diabetes 
Ischaemic heart disease 
Current steroid use 
Other co-morbidities 
 
38 (4.3) 
25 (2.8) 
13 (1.5) 
363 (41.3) 
Previous and neoadjuvant cancer therapies 
Previous radiotherapy to the ipsilateral breast 
Neoadjuvant chemotherapy 
Neoadjuvant endocrine therapy 
Neoadjuvant radiotherapy 
 
 6 (0.7) 
104 (11.8) 
54 (6.1) 
4 (0.5) 
Previous breast surgery, n (%), N=899 breasts 67 (7.5) 
American Society of Anesthesiologists (ASA) grade 
Grade 1 
Grade 2 
Grade 3 
Not reported 
 
295 (33.5) 
535 (60.8) 
46 (5.2) 
4 (0.5) 
Presentation 
Screening 
Symptomatic 
Not reported 
 
424 (48.1) 
454 (51.6) 
2 (0.2) 
BMI – body mass index, IQR – interquartile range 
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Table 2 Pre-operative planning and surgical decision making 
 Total TM breasts (n=899) (%) 
Predominant location of tumour by quadrant  
Upper outer 379 (42.2) 
Upper inner 180 (20.0) 
Lower outer 133 (14.8) 
Lower inner 109 (12.1) 
Central (immediately behind nipple) 75 (8.3) 
Not reported 23 (2.6) 
Pre-operative assessment of lesion  
DCIS 146 (16.2) 
Invasive ductal carcinoma 605 (67.3) 
Invasive lobular carcinoma 79 (8.8) 
Other 53 (5.9) 
Not reported 16 (1.8) 
Provisional invasive grade (n=737)  
Grade 1 121 
Grade 2 409 
Grade 3 192 
Provisional grade of DCIS (n=146)  
Low grade 9 
Intermediate grade 37 
High grade 95 
Maximum size of lesion at diagnosis, mm (median, IQR, range) 24 (15-35) (2-120) 
Multifocal 169 (18.8) 
Surgical decision-making Per patient (n=880) (%) 
Contralateral symmetrisation  
Planned simultaneous to TM procedure 283 (31.5) 
Planned for a later date 126 (14.0) 
To be discussed later 246 (38.5) 
Patient declined 65 (7.2) 
Not applicable – bilateral disease 38 (4.2) 
Not reported 41 (4.6) 
Indications for therapeutic mammaplastya  
Large tumour 197 (21.9) 
To avoid mastectomy 379 (42.2) 
To avoid poor cosmetic outcome associated with standard wide local 
excision 
702 (78.1) 
To avoid problems associated with radiotherapy in large breasts 160 (17.8) 
Quality of life benefits 250 (27.8) 
Other 40 (4.5) 
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Other treatment options offereda  
Standard wide local excision 590 (65.6) 
Mastectomy alone 375 (41.7) 
Mastectomy with immediate implant reconstruction  270 (30.0) 
Mastectomy with immediate autologous reconstruction 231 (25.7) 
DCIS – ductal carcinoma in situ; IQR – interquartile range; TM – therapeutic mammaplasty 
aMore than one indication or treatment option could be given per patient 
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Table 3 Operative data 
 N=899, (%) 
Duration of the procedure, minutes (median, IQR, range) 110.5 (90-150) (39-420) 
Grade of operating surgeon  
Consultant 771 (85.8) 
Senior trainee (Oncoplastic Fellow/ST8) 85 (9.5) 
Junior trainee (ST7 or below) 16 (1.8) 
Associate Specialist/Other 22 (2.4) 
Not reported 5 (0.6) 
Number of TMs performed using similar technique unsupervised by the operating 
surgeon 
 
<5 73 (8.1) 
5-10 22 (2.5) 
10-25 87 (9.7) 
>25 671 (74.6) 
Not reported 46 (5.1) 
Pre-operative tumour localisation  
Any method 600 (66.7) 
Bracketing wires or equivalent 170 (18.9) 
Skin incision used 
Wise pattern (inverted T) 
Peri/circumareolar with skin excision (e.g. round block, Benelli or racquet) 
Single vertical scar (Le Jour) 
Grisotti (for central cancers removing nipple-areolar complex, NAC) 
Melon-slice (horizontal wedge excision +/- NAC excision) 
Other 
Not reported 
 
429 (47.7) 
232 (25.8) 
135 (15.0) 
16 (1.8) 
28 (3.1) 
55 (6.1) 
4 (0.4) 
Nipple preservation 
On a pedicle 
As a free nipple graft 
Nipple not preserved 
Not reported 
 
828 (92.1) 
10 (1.1) 
57 (6.3) 
4 (0.4) 
Pedicle used to preserve nipple (if nipple preserved n=828) 
Superior 
Superiomedial 
Medial 
Inferior 
Central mound 
Dual pedicle 
Other/not reported 
 
81 (9.8) 
201 (24.3) 
21 (2.5) 
204 (24.6) 
225 (27.2) 
45 (5.4) 
51(6.2) 
Method of tumour excision 
WLE performed first followed by reduction/mastopexy 
WLE incorporated in reduction specimen (both performed simultaneously) 
Not reported 
 
378 (42.0) 
520 (57.8) 
1 (0.1) 
Intra-operative confirmation of tumour excision  
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None 
Specimen radiography 
Other intra-operative assessment method (e.g. frozen section) 
Not reported 
90 (10.0) 
785 (87.3) 
19 (2.1) 
5 (0.6) 
Weight of wide local excision, grams (median, IQR, range) 83 (44-173) (6-1545) 
Total weight of breast tissue excised, grams (median, IQR, range)  126.5 (50-319) (5-2522) 
Method of marking tumour bed 
None 
Single clip 
Clips to all margins 
Not reported 
 
44 (4.9) 
16 (1.8) 
836 (93.0) 
3 (0.3) 
Axillary surgery performed 
None 
Sentinel node biopsy 
Axillary node clearance 
 
134 (14.9) 
666 (74.1) 
99 (11.0) 
Drains used 296 (32.9) 
Procedure performed to the contralateral breast (n=880 patients)  
None 562 (63.7) 
Contralateral reduction/mastopexy 284 (32.3) 
Bilateral therapeutic mammaplasties 19 (2.2) 
Mastectomy only 2 (0.2) 
Mastectomy and implant reconstruction 2 (0.2) 
Mastectomy and autologous reconstruction 1 (0.1) 
Not reported 10 (1.1) 
IQR – interquartile range, WLE - wide local excision 
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Table 4. Complications at 30 days per breast and per patient 
 
Complication 
Per breast data 
Therapeutic 
mammaplasty (N=899) 
n (%) 
Contralateral 
reduction/mastopexy 
(N=284) n (%) 
Seroma requiring aspiration 35 (3.9) 1 (0.4) 
Haematoma 
Managed conservatively 
Requiring surgical evacuation  
24 (2.3) 
15 (1.7) 
9 (1) 
6 (2.1) 
2 (0.7) 
4 (0.1) 
Infection 
Requiring oral antibiotics 
Requiring IV antibiotics 
Requiring surgical debridement/drainage 
64 (7.1) 
53 (5.9) 
6 (0.7) 
5 (0.6) 
18 (6.3) 
17 (6) 
0 
1 (0.3) 
Skin necrosis, including T junction necrosis 
Minor – managed conservatively 
Major requiring surgical debridement 
59 (6.6) 
56 (6.2) 
3 (0.3) 
22 (7.7) 
21 (7.4) 
1 (0.3) 
Nipple necrosis  
Minor managed conservatively 
Requiring debridement 
(n=828)* 
8 (1.0) 
2 (0.2) 
(n=284)* 
1 (0.4) 
0 (0.0) 
Wound dehiscence 
Managed conservatively 
Requiring return to theatre 
45 (5.0) 
42 (4.6) 
3 (0.3) 
9 (3.2) 
7 (2.5) 
2 (0.7) 
Any complication 181 (20.1) 42 (14.8) 
 
 Per patient data (n=880) 
Any surgical complication within 30 days of TM procedure 205 (23.3) 
Re-operation for complications within 30 days of TM 25 (2.8) 
In hospital complications 
Reaction to blue dye 
Surgical complicationa 
Medical complicationb 
Other 
12 (1.3) 
2 (0.2) 
5 (0.6) 
2 (0.2) 
3 (0.3) 
Readmission for complications following discharge within 30 
days of surgeryc 
12 (1.4) 
Length of stay 
Daycase 
23 hour 
Inpatient 
Not reported 
 
351 (39.9) 
232 (26.4) 
289 (32.8) 
8 (0.9) 
*Denominator is breasts that kept their nipple on a pedicle; aHaematomas requiring evacuation, bCardiac arrhythmias 
cincluded admission for intravenous antibiotic (n=4); evacuation of haematoma (n=2); debridement of nipple necrosis (n=1); 
drainage of recurrent seroma (n=1) and recurrent SVTs (n=1) 
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Table 5. Risk factors for post-operative complications 
  
Variable 
Univariable p-value Multivariable (N=790, 
events=185) 
p-value 
N (events, %) Odds Ratio (95% CI) Odds Ratio (95% CI) 
Age (per year increase) 873 (204, 23%) 1.00 (0.98, 1.01) 0.652   
Current smoker 
No 
Yes 
863 (204, 24%) 
774 (171, 22%) 
89 (33, 37%) 
 
Reference 
2.08 (1.35, 3.20) 
 
 
0.001* 
 
 
2.32 (1.51, 3.56) 
 
 
<0.001** 
BMI, kg/m2 
Normal <25 
Overweight 25-29 
Obese 30-34 
Severely obese 35+ 
853 (201, 24%) 
200 (29, 15%) 
309 (68, 22%) 
213 (63, 30%) 
131 (41, 31%) 
 
Reference 
1.66 (1.03, 2.68) 
2.48 (1.55, 3.95) 
2.69 (1.52, 4.76) 
 
 
0.037* 
<0.001* 
0.001* 
 
Reference 
1.25 (0.77, 2.04) 
1.73 (1.05, 2.86) 
1.77 (0.96, 3.27) 
 
 
0.363 
0.033** 
0.066 
Diabetes 
No 
Yes 
870 (203, 23%) 
832 (197, 24%) 
38 (6, 16%) 
 
Reference 
0.60 (0.25, 1.44) 
 
 
0.254 
  
Any comorbidities 
No 
Yes 
880 (205, 23%) 
490 (106, 22%) 
390 (99, 25%) 
 
Reference 
1.23 (0.92, 1.66) 
 
 
0.167 
  
ASA grade 
Grade 1 
Grade 2 
Grade 3 
876 (204, 23%) 
295 (50, 17%) 
535 (140, 26%) 
46 (14, 30%) 
 
Reference 
1.74 (1.25, 2.41) 
2.14 (1.02, 4.49) 
 
 
0.001* 
0.043* 
 
Reference 
1.45 (1.07, 1.96) 
1.68 (0.71, 3.98) 
 
 
0.018** 
0.236 
Neoadjuvant chemotherapy 
No 
Yes 
879 (205, 23%) 
775 (179, 23%) 
104 (26, 25%) 
 
Reference 
1.11 (0.68, 1.82) 
 
 
0.681 
  
Surgeon grade 
Trainee 
Consultant 
876 (203, 23%) 
121 (34, 28%) 
755 (169, 22%) 
 
Reference 
0.74 (0.53, 1.04) 
 
 
0.078 
  
Surgical experience 
≤25 similar procedures  
>25 similar procedures 
866 (201, 23%) 
103 (32, 31%) 
763 (169, 22%) 
 
Reference 
0.63 (0.41, 0.97) 
 
 
0.034* 
 
 
0.60 (0.41, 0.88) 
 
 
0.010** 
Skin incision type 
Other than wise pattern 
Wise pattern 
876 (204, 23%) 
462 (72, 16%) 
414 (132, 32%) 
 
Reference 
2.54 (1.87, 3.44) 
 
 
<0.001* 
 
 
1.90 (1.20, 3.00) 
 
 
0.006** 
Unilateral or bilateral surgery  
Unilateral TM 
TM + contralateral symmetrisation 
Bilateral TM 
880 (205, 23%) 
577 (107, 19%) 
284 (89, 31%) 
19 (9, 47%) 
 
Reference 
2.00 (1.33, 3.02) 
3.95 (1.33, 11.78) 
 
 
0.001* 
0.014* 
 
Reference 
1.32 (0.70, 2.47) 
3.40 (0.82, 14.10) 
 
 
0.389 
0.092 
Axillary surgery 
None 
Sentinel node biopsy 
Axillary node clearance 
880 (205, 23%) 
129 (31, 24%) 
653 (146, 22%) 
98 (28, 29%) 
 
Reference 
0.91 (0.55, 1.52) 
1.26 (0.67, 2.40) 
 
 
0.720 
0.473 
 
 
 
 
 
Specimen weight (per 10g increase) 842 (196, 23%) 1.01 (1.01, 1.02) <0.001* 1.00 (1.00, 1.01) 0.612 
Drains used 
No 
Yes 
873 (202, 23%) 
584 (117, 20%) 
289 (85, 29%) 
 
Reference 
1.66 (1.20, 2.30) 
 
 
0.002* 
 
 
1.16 (0.82, 1.64) 
 
 
0.400 
Procedure duration (per extra hour)a 400 (93, 23%) 1.74 (1.33, 2.29) <0.001a   
*=p<0.1 therefore put variable put forward to multivariable analysis. **=p<0.05 therefore strong association with having a post-
operative complication in the multivariable analysis 
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aProcedure duration is highly significant in the univariate analysis, but given the high level of missing data (n=480), this variable was 
not carried forward to the multivariable analysis 
ASA – American Society of Anaesthesiologists; BMI – body mass index, TM – therapeutic mammaplasty 
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Table 6. Post-operative histology and tumour characteristics in therapeutic 
mammaplasty cases with complete and incomplete excision margins  
 Per breast: N=899 (%)* 
Post-operative histology Completely excised 
N=744 (82.8%) 
Incompletely excised 
N=132 (14.7%) 
Type of lesion 
Ductal carcinoma in situ 
Invasive ductal carcinoma 
Invasive lobular carcinoma 
Other invasive 
Not reported 
 
108 (14.5) 
512 (68.8) 
74 (10.0) 
46 (6.2) 
4 (0.5) 
 
24 (18.2) 
81 (61.4) 
15 (11.4) 
12 (9.1) 
0 (0.0) 
Grade  
Invasive (n=744) 
Grade 1 
Grade 2 
Grade 3 
Not reported 
Ductal carcinoma in situ (DCIS) (n=132) 
Low grade 
Intermediate grade 
High grade 
 
 
110 (13.6) 
302 (40.6) 
217 (29.2) 
124 (16.7) 
 
10 (9.3) 
30 (27.8) 
68 (63.0) 
 
 
16 (12.1) 
58 (43.9) 
32 (24.2) 
26 (19.7) 
 
0 (0.0) 
3 (12.5) 
21 (87.5) 
Multifocal tumour 
No 
Yes 
Not reported 
 
606 (81.5) 
133 (17.8) 
5 (0.7) 
 
72 (54.5) 
59 (44.7) 
1 (0.8) 
Size of largest invasive tumour, mm (median, IQR, range)** 18 (10, 26) (0-155)a 22 (13, 37) (0-145)b 
Total size of lesion including DCIS, mm (median, IQR, range)** 23 (15, 34) (0-144)c 39 (25, 54) (5-145)d 
Receptor status*** 
ER positive 
HER-2 positive 
Not reported 
 
565 (75.9) 
108 (14.5) 
71 (9.5) 
 
90 (68.2) 
19 (14.4) 
23 (17.4) 
Lymph node status (n=765) 
Number of lymph nodes involved - macrometastases only (median, IQR, 
range)  
N0 
N1 
 
 
0 (0-0) (0-25) 
495 (66.5) 
77 (10.4) 
 
 
0 (0-0) (0-18) 
82 (62.1) 
9 (6.8) 
*23 (2.6%) did not have data recorded on whether or not there was complete excision 
**Including patients who had a complete pathological response with neoadjuvant chemotherapy; ***Denominator is those with 
invasive lesions; ER – oestrogen receptor; IQR – interquartile range; MDT – multidisciplinary team 
aNot reported for 35 bNot reported for 11 cNot reported for 45 dNot reported for 6 
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Table 7. Risk factors for incomplete excision of tumour according to local MDT criteria 
  
Variable 
  
Univariable 
 
 
Multivariable (N=859, events=130) 
 
N (events, %) Odds Ratio 
(95% Confidence 
Interval) 
p-value Odds Ratio 
(95% Confidence 
Interval) 
p-value 
Age (per year increase) 869 (130, 15%) 0.99 (0.98, 1.01) 0.441   
Neoadjuvant chemotherapy 
No 
Yes 
875 (131, 15%) 
774 (121, 16%) 
101 (10, 10%) 
 
Reference 
0.59 (0.27, 1.29) 
 
 
0.188 
  
Maximum pre-operative size (as 
per 5mm increases) 
862 (131, 15%) 1.07 (1.02, 1.11) 0.002* 1.06 (1.02, 1.11) 0.009** 
Pre-op multifocality 
No 
Yes 
872 (131, 15%) 
706 (98, 14%) 
166 (33, 20%) 
 
Reference 
1.54 (1.08, 2.20) 
 
 
0.019* 
 
Reference 
1.48 (1.02, 2.14) 
 
 
0.038** 
Pre-op localisation 
No 
Yes 
865 (131, 15%) 
279 (36, 13%) 
586 (95, 16%) 
 
Reference 
1.31 (0.93, 1.82) 
 
 
0.117 
  
Specimen imaging 
No 
Yes 
872 (131, 15%) 
87 (8, 9%) 
785 (123, 16%) 
 
Reference 
1.83 (0.84, 4.02) 
 
 
0.129 
  
Disease type 
DCIS 
Invasive 
814 (120, 15%) 
132 (24, 18%) 
682 (96, 14%) 
 
Reference 
0.74 (0.46, 1.18) 
 
 
0.208 
  
Positive nodal status  
N0 
N1/N2 
744 (107, 14%) 
577 (82, 14%) 
167 (25, 15%) 
 
Reference 
1.06 (0.65, 1.73) 
 
 
0.806 
  
Positive HER-2 Status 
No 
Yes 
758 (108, 14%) 
127 (19, 15%) 
631 (89, 14%) 
 
Reference 
0.93 (0.55, 1.58) 
 
 
0.798 
  
Positive ER Status 
No 
Yes 
784 (112, 14%) 
655 (90, 14%) 
129 (22, 17%) 
 
Reference 
1.29 (0.72, 2.31) 
 
 
0.391 
  
Ductal vs lobular invasive 
disease  
Ductal 
Invasive lobular 
Other 
872 (132, 15%) 
725 (105, 14%) 
89 (15, 17%) 
58 (12, 21%) 
 
 
Reference 
1.20 (0.70, 2.03) 
1.54 (0.81, 2.92) 
 
 
 
0.506 
0.185 
 
 
 
 
 
 
 
 
Grade of invasive disease on 
post-operative pathology 
Ductal carcinoma in situ (DCIS) 
1 
2 
3 
858 (130, 15%) 
 
132 (24, 18%) 
117 (16, 14%) 
360 (58, 16%) 
249 (32, 13%) 
 
 
1.40 (0.81, 2.43) 
Reference 
1.21 (0.74, 1.98) 
0.93 (0.53, 1.63) 
 
 
0.229 
 
0.442 
0.803 
 
 
 
 
 
 
 
 
Presentation type 
Symptomatic 
Screening 
875 (132, 15%) 
419 (66, 16%) 
456 (66, 14%) 
 
Reference 
0.91 (0.63, 1.30) 
 
 
0.592 
  
Specimen weight (per 10g 
increase) 
840 (126, 15%) 0.99 (0.99, 1.00) 0.274   
*= P<0.1 therefore put variable put forward to multivariable analysis. **=P<0.05 strong association with incomplete excision in the 
multivariable analysis 
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Table 8.  Multidisciplinary team decision-making and time to adjuvant therapy 
Adjuvant treatment recommendations and time to adjuvant therapy Per patient: N=880 n (%) 
Chemotherapy   
Not recommended 509 (57.8) 
Chemotherapy recommended 273 (31.0) 
Chemotherapy accepted 228 (25.9) 
Chemotherapy previously given 78 (9.1) 
Missing 20 (2.3) 
Radiotherapy   
Not recommended 67 (7.6) 
Recommended 794 (90.2) 
Already given 2 (0.2) 
Missing 17 (1.9) 
Adjuvant chemotherapy and/or radiotherapy required 811 (92.2) 
Time to first adjuvant therapy (n=695) (days) (median, IQR, range) 54 (42-66) (6-287) 
Time to chemotherapy as first adjuvant therapy (n=204) (days) (median, IQR, range) 47 (30-58) (14-237) 
Time to radiotherapy as first adjuvant therapy (n=491) (days) (median, IQR, range) 56 (44-69) (6-287) 
IQR – interquartile range 
 
